Alcohol
Volume 24, Issue 1 , Pages 15-23 , May 2001

Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype

  • Matts Eriksson

      Affiliations

    • Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
    • ,
  • Ulf Berggren

      Affiliations

    • Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
    • ,
  • Kaj Blennow

      Affiliations

    • Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
    • ,
  • Claudia Fahlke

      Affiliations

    • Department of Psychology, Göteborg University, Göteborg, Sweden
    • ,
  • Jan Balldin

      Affiliations

    • Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46-31-343-23-72; fax: +46-31-343-23-48

Received 18 February 2000 ,Revised 19 January 2001 ,Accepted 31 January 2001.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th edn.. Washington, DC: American Psychiatric Association Press; 1994;
  2. Åkefeldt A, Månsson JE. Is monoamine oxidase activity elevated in Prader–Willi syndrome?. Eur Child Adolesc Psychiatry. 1998;7:163–165
  3. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, et al. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49:599–608
  4. Balldin J, Berggren U, Engel J, Eriksson M. Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking. Alcohol Clin Exp Res. 1994;18:822–825
  5. Balldin J, Berggren U, Engel J, Eriksson M, Hård E, Söderpalm B. Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res. 1994;18:1133–1136
  6. Ballenger JC, Goodwin FK, Major LF, Brown GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979;36:224–227
  7. Banki CM. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Transm. 1981;50:89–101
  8. Berggren, U., Eriksson, M., Fahlke, C., Balldin, J. (In press). Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram. Drug and Alcohol Dependence
  9. Borg S, Kvande H, Liljeberg P, Mossberg D, Valverius P. 5-Hydroxyindoleacetic acid in cerebrospinal fluid in alcoholic patients under different clinical conditions. Alcohol. 1985;2:415–418
  10. Buydens-Branchey L, Branchey M, Fergeson P, Hudson J, McKernin C. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics. Alcohol Clin Exp Res. 1997;21:220–226
  11. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse. Cross-fostering analysis of adopted women. Arch Gen Psychiatry. 1981;38:861–868
  12. Colton T. Statistics in Medicine. Boston: Little, Brown; 1974;
  13. Engel JA, Enerback C, Fahlke C, Hulthe P, Hård E, Johannessen K, et al. Serotonergic and dopaminergic involvement in ethanol intake. In:  Naranjo CA,  Sellers EM editor. Novel Pharmacological Interventions for Alcoholism. New York: Springer-Verlag; 1992;p. 68–82
  14. Fils-Aime ML, Eckardt MJ, George DT, Brown GL, Mefford I, Linnoila M. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry. 1996;53:211–216
  15. Geijer T, Neiman J, Rydberg U, Gyllander A, Jönsson E, Sedvall G, et al. Dopamine D2-receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur Arch Psychiatry Clin Neurosci. 1994;244:26–32
  16. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261–265
  17. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet. 1993;2:2197
  18. Hamilton M. The assessment of anxiety states by rating. Br J Psychol. 1959;32:50–55
  19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–296
  20. Hasin D, Paykin A. Dependence symptoms but no diagnosis: diagnostic “orphans” in a 1992 national sample. Drug Alcohol Depend. 1999;53:215–222
  21. Higley JD, Bennett AJ. Central nervous system serotonin and personality as variables contributing to excessive alcohol consumption in non-human primates. Alcohol Alcohol. 1999;34:402–418
  22. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996;20:780–784
  23. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive–behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534–1541
  24. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391–397
  25. Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med. 1995;1:337–341
  26. Lee MA, Melzer HY. Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry. 1991;30:1017–1030
  27. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry. 1994;36:326–337
  28. Maurel S, De Vry J, Schreiber R. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Alcohol. 1999;17:195–201
  29. Naranjo CA, Bremner KE, Lanctôt KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction. 1995;90:87–99
  30. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990;47:490–498
  31. Naranjo CA, Poulos CX, Bremner KE, Lanctôt KL. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992;51:729–739
  32. Naranjo CA, Sellers EM. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. In:  Galanter M editors. Recent Developments in Alcoholism. 7:New York: Plenum; 1989;p. 255–266
  33. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984;35:374–381
  34. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin reuptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987;41:266–274
  35. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther. 1989;46:301–309
  36. Noble EP. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol. 1998;16:33–45
  37. Pollock NK, Martin CS. Diagnostic orphans: adolescents with alcohol symptoms who do not qualify for DSM-IV abuse or dependence diagnoses. Am J Psychiatry. 1999;156:897–901
  38. Sellers EM, Higgins GA, Sobel MB. 5-HT and alcohol abuse. Trends Pharmacol Sci. 1992;13:69–75
  39. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988;83:393–402
  40. Tiihonen J, Ryynänen OP, Kauhanen J, Hakola HPA, Salaspuro M. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry. 1996;29:27–29
  41. Virkkunen M, Linnoila M. Serotonin in early onset, male alcoholics with violent behaviour. Ann Med. 1990;22:327–331

PII: S0741-8329(01)00137-9

Alcohol
Volume 24, Issue 1 , Pages 15-23 , May 2001

Article Tools

* Image Usage & Resolution